Daily Alpha · Reddit
· Premarket Alpha · by Buzzberg Research
Themes on this desk
AI dip accumulation
Retail dismissed the OpenAI revenue scare as an accounting artifact and added NVDA, ORCL, CRWV, MU, SNDK and SOXL into the selloff; one bear essay argued OpenAI's dependence on fresh capital still threatens the whole complex.
India IT
A new US immigration policy hit Nifty sentiment — the index had already crashed to an 18-month low of 22,231.80 — while TCS's 2.5% dollar revenue growth reinforced IT worries; one thread argued falling US yields could still spark a Nifty re
Highest engagement
by score · day changeA $10,000 TLT put bet against long-dated Treasuries
The poster discloses putting $10,000 into TLT puts, an outright bet that long-dated Treasury prices fall.
Dumped 10k on TLT puts, let’s see if Bessent “The house” will make me go broke
A concrete retail short in duration while the long end stays central to the macro debate.
Watch Whether long-dated Treasury prices fall as the trade intends.
Source →Retail stacks long-dated Energy Transfer calls
The poster says they bought about 200 Energy Transfer 2029 $20 calls, with a breakeven near $22.50.
I recently bought $20C for 2029 on ET. I have like 200 or so.
A multi-year call position on midstream energy is a concrete retail bet on durable cash flows.
Watch Energy Transfer's distribution updates and the unit price relative to the roughly $22.50 breakeven.
Source →Coursera pitched as a cash-backed forced-seller setup into Q3
The write-up says the 11-million-share forced seller has been absorbed, flags a 66% cash backstop, and argues Wall Street's share count is stale ahead of a likely Q3 EPS beat from share-count compression.
$COUR: 11M Forced Seller Hit 0.0%, 66% Cash Backstop, and Wall Street Has the Wrong Share Count Ahead of Q3
A small-cap value setup where the Q3 print is the catalyst and buyback or activist demand is the second leg.
Watch Coursera's Q3 results and any buyback or activist confirmation.
Source →Compass Pathways pitched as the first FDA-approved psilocybin therapy
The bull case says Comp360 could become the first FDA-approved psilocybin therapy, with an NDA filing imminent and a large treatment-resistant depression and PTSD opportunity.
Compass Pathways (CMPS)-first FDA-approved psychedelic to market Are there other investors in CMPS here?
A binary regulatory catalyst with a defined filing timeline in a small-cap biotech.
Watch NDA submission and FDA acceptance milestones.
Source →Retail loads Tesla calls into the Roadster event
One poster says anyone skipping the Tesla Roadster event — via calls or puts — is foolish, and discloses buying calls.
If you arent full porting into the Tesla Roadster event, either with calls or puts, youre truly regarded.
Event-driven options demand around a headline catalyst can amplify single-stock volatility.
Watch The Roadster event outcome and the post-event volatility crush.
Source →Most argued
by comments per upvoteRetail builds a staples-and-dividend 'boomer' basket
A poster reports buying 100 PepsiCo shares, 100 Procter & Gamble shares and 400 SCHD units, describing the result as a boomer-style portfolio.
Nice. That day I also bought 100 shares of Pepsi, proctor and gamble, and 400 SCHD.
Shows retail appetite for defensive yield as an alternative to crowded growth trades.
Watch PepsiCo's organic-sales trend and SCHD's relative performance.
Source →Earnings week watchlist, can't stop staring at TSM next Thursday
Earnings-week watchlist with a bullish TSM options setup, a neutral ASML read-through, and explicit skips of UNH, JPM and JNJ.
Earnings week watchlist, can't stop staring at TSM next Thursday Stuff I'm watching next week.Source →